Please assess the completion status of the following clinical trial:

Trial Title: Progel Vascular Sealant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Subject must be ≥ 18 years of age.~* 2. Subject is scheduled for elective, primary thoracic surgery involving the aortic valve, ascending aorta, or aortic arch on cardiopulmonary bypass.~* 3. Subject has an expected life expectancy\> 6 months.~* 4. Subject is willing and able to comply with all aspects of the study including follow-up schedule.~* 5. Subject or authorized representative, has the ability to provide voluntary written informed consent.~Intra-operative Inclusion Criteria:~* 1. Subject is able to undergo an antegrade cardioplegia injection for evaluation of a leak at the aortic anastomotic site(s) during the procedure.~* 2. Following this injection, subject has a leaking site where a topical sealant/hemostatic agent may be used to control bleeding.~Exclusion Criteria:~* 1. Subject has Type A or other acute thoracic aortic dissection.~* 2. Subject has undergone prior thoracic surgery (open thoracotomy not including interventional cardiology procedures).~* 3. Subject is undergoing a planned concomitant procedure other than coronary artery bypass graft (CABG).~* 4. Subject has a previous organ transplant.~* 5. Subject has known or suspected preoperative coagulation disorder.~* 6. Subject is allergic to human thrombin or has a history of allergic reactions after application of human thrombin.~* 7. Subject is allergic to protamine.~* 8. Subject has a Left Ventricular Assist Device (LVAD) or planned to receive an LVAD.~* 9. Subject is undergoing emergency surgery.~* 10. Subject is in chronic renal failure.~* 11. Subject has a hematocrit \< 21% pre-operatively.~* 12. Subject has a serum creatinine ≥2.5 mg/dl at baseline or is currently on dialysis.~* 13. Subject has a cardiac ejection fraction \<25%.~* 14. Subject is scheduled for another cardiac surgery within 30 days of enrollment.~* 15. Subject has an active or latent infection which is systemic or at the intended surgery site.~* 16. Subject is immuno-compromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders.~* 17. Subject is pregnant by a positive pregnancy test or has plans to become pregnant during the study period or is currently breast-feeding.~* 18. Subject is unwilling to receive blood products.~* 19. Subject has participated in another investigational research study within 30 days of enrollment.~* 20. In the opinion of the investigator, the subject has a clinical condition that would preclude the use of the study device, preclude the subject from completing the follow-up requirements, or would complicate the evaluation of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Progel Vascular Sealant (Type: EXPERIMENTAL): Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
- Gelfoam Plus (Type: ACTIVE_COMPARATOR): Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete